Page last updated: 2024-10-20

uracil and Chemotherapy-Induced Febrile Neutropenia

uracil has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder

Chemotherapy-Induced Febrile Neutropenia: FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

Research Excerpts

ExcerptRelevanceReference
"TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC)."3.83Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. ( Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kasi, PM1
Kotani, D1
Cecchini, M1
Shitara, K1
Ohtsu, A1
Ramanathan, RK1
Hochster, HS1
Grothey, A1
Yoshino, T1

Other Studies

1 other study available for uracil and Chemotherapy-Induced Febrile Neutropenia

ArticleYear
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    BMC cancer, 2016, 07-13, Volume: 16

    Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Clinical Trials,

2016